Moffitt Experts Recommend New Guidelines for CAR T-Cell Therapy Trials

Current FDA guidelines may cause promising cancer treatments to be abandoned too soon.

At the Heart of the Cancer Battle

Moffitt’s Cardio-Oncology Program keeps hearts healthy during and after cancer treatment

Top Moffitt Research Stories of 2024

From FDA approvals to drug discovery, Moffitt led the way this past year

Can a Ketogenic Diet Boost Effectiveness of Cancer Immunotherapy?

Study finds that a compound from ketosis helps fuel the CAR T cells, making them more effective at attacking cancer

New CAR T-Cell Therapy Shows Promising Results for Advanced Multiple Myeloma

Early trial results show high success rates and manageable side effects

Moffitt Study Explores Key Risk Factors To Better Personalize CAR T-Cell Therapy

The study analyzed ide-cel to help physicians intervene and reduce toxicities in multiple myeloma patients

Largest Comprehensive Study Compares Efficacy of CAR T Products for Multiple Myeloma

Cilta-cel demonstrates greater effectiveness than ide-cel but carries higher toxicities, study finds

Moffitt Patient Is First To Receive Second CAR T Therapy for Ovarian Cancer

Patient receives second dose of CAR-T immunotherapy for ovarian cancer with special approval from the FDA.

Endeavor